Literature DB >> 23486458

Cervical cancer.

Wui-Jin Koh1, Benjamin E Greer, Nadeem R Abu-Rustum, Sachin M Apte, Susana M Campos, John Chan, Kathleen R Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J Eifel, David K Gaffney, Robert L Giuntoli, Ernest Han, Warner K Huh, John R Lurain, Lainie Martin, Mark A Morgan, David Mutch, Steven W Remmenga, R Kevin Reynolds, William Small, Nelson Teng, Todd Tillmanns, Fidel A Valea, Nicole R McMillian, Miranda Hughes.   

Abstract

These NCCN Clinical Practice Guidelines in Oncology for Cervical Cancer focus on early-stage disease, because it occurs more frequently in the United States. After careful clinical evaluation and staging, the primary treatment of early-stage cervical cancer is either surgery or radiotherapy. These guidelines include fertility-sparing and non-fertility-sparing treatment for those with early-stage disease, which is disease confined to the uterus. A new fertility-sparing algorithm was added for select patients with stage IA and IB1 disease..

Entities:  

Mesh:

Year:  2013        PMID: 23486458     DOI: 10.6004/jnccn.2013.0043

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  39 in total

1.  Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+ cervical cancer via sponging miR-145.

Authors:  Hongzhi Lu; Yu He; Lin Lin; Zhengqin Qi; Li Ma; Li Li; Ying Su
Journal:  Tumour Biol       Date:  2015-08-27

Review 2.  A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results.

Authors:  Michelle J Khan; L Stewart Massad; Walter Kinney; Michael A Gold; E J Mayeaux; Teresa M Darragh; Philip E Castle; David Chelmow; Herschel W Lawson; Warner K Huh
Journal:  Gynecol Oncol       Date:  2016-02-22       Impact factor: 5.482

3.  Cervical cancer is addicted to SIRT1 disarming the AIM2 antiviral defense.

Authors:  Daeho So; Hyun-Woo Shin; Jiyoung Kim; Mingyu Lee; Jongyun Myeong; Yang-Sook Chun; Jong-Wan Park
Journal:  Oncogene       Date:  2018-05-29       Impact factor: 9.867

4.  Positron-emission tomography for locally advanced cervical cancer: a survey assessing Canadian practice patterns and access.

Authors:  R Banerjee; G Dundas; C Doll
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

5.  Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?

Authors:  Neil T Phippen; Charles A Leath; Laura J Havrilesky; Jason C Barnett
Journal:  Gynecol Oncol       Date:  2014-11-09       Impact factor: 5.482

6.  Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.

Authors:  Yan Xiao; Ying-Kun Ren; Hui-Jun Cheng; Li Wang; Su-Xia Luo
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

7.  Added value of diffusion-weighted MRI in detection of cervical cancer recurrence: comparison with morphologic and dynamic contrast-enhanced MRI sequences.

Authors:  Rita Lucas; João Lopes Dias; Teresa Margarida Cunha
Journal:  Diagn Interv Radiol       Date:  2015 Sep-Oct       Impact factor: 2.630

8.  The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.

Authors:  N L Robertson; H Hricak; Y Sonoda; R E Sosa; M Benz; G Lyons; N R Abu-Rustum; E Sala; H A Vargas
Journal:  Gynecol Oncol       Date:  2016-01-11       Impact factor: 5.482

9.  Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring.

Authors:  Zhigang Kang; Sanja Stevanović; Christian S Hinrichs; Liang Cao
Journal:  Clin Cancer Res       Date:  2017-09-12       Impact factor: 12.531

10.  [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results.

Authors:  Karsten Beiderwellen; Johannes Grueneisen; Verena Ruhlmann; Paul Buderath; Bahriye Aktas; Philipp Heusch; Oliver Kraff; Michael Forsting; Thomas C Lauenstein; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.